Oxidative stress as a cause of Parkinson's disease

Acta Neurologica Scandinavica

Volumn 84, Issue 136 S, 1991, Pages 6-15

  Jenner, P ^a,b  

^a Institute of Neurology   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

iron levels; mitochondrial function; MPTP; oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; IRON; SELEGILINE;

ANIMAL; BRAIN; CELL SURVIVAL; DRUG EFFECT; HUMAN; IATROGENIC DISEASE; LIPID PEROXIDATION; METABOLISM; MITOCHONDRION; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; ULTRASTRUCTURE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; STRESS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMAL; BRAIN; CELL SURVIVAL; DOPAMINE; HUMAN; IRON; LIPID PEROXIDATION; MITOCHONDRIA; NEURONS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; SUPPORT, NON-U.S. GOV'T;

EID: 0026337175     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1991.tb05013.x     Document Type: Article

References (92)

1. The cause of Parkinson's disease
2. Comparison of neuronal loss in Parkinson's disease and aging
3. Striatal function in normal aging: Implications for Parkinson's disease
4. The role of environmental toxins in the etiology of Parkinson's disease
5. Xenobiotic metabolism in Parkinson's disease
6. S‐methylation in motorneuron disease and Parkinson's disease
7. Chronic parkin‐sonism secondary to intravenous injection of meperidine analogues
8. Chronic parkinsonism in humans due to a product of meperidineanalog synthesis
9. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydro‐pyridine
10. Selective nigral toxicity after systemic administration of 1‐methyl‐4‐phenyl‐1, 2, 5, 6‐tetrahydropyridine (MPTP) in the squirrel monkey
11. I‐Methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐induced parkinsonism in the common marmoset
12. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine
13. Effect of long‐term administration of 1, 2, 3, 4‐tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4‐dihydroxyphenylacetic acid (DOPAC) content in mice
14. Dopamine uptake inhibitory capacities of B‐carboline analogs of N‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP) oxidation products
15. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1‐deprenyl
16. Neuromelanin and Parkinson's disease
17. Parkinson's disease: clues to the cause of cell death in the substantia nigra
18. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
19. Oxidation of the neurotoxic amine 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tertrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes of MPTP
20. Studies on the oxidation of the doparninergic neurotoxin 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine by monoamine oxidase B
21. Potential bioactivation pathways for the neurotoxin 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP)
22. Model study of the bioreduction of paraquat, MPP+, and analogs
23. Biochemical mechanisms of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine toxicity
24. 1‐Methyl‐4‐phenylpyridinium (MPP+) induces NADH‐dependent superoxide formation and enhances NADH‐dependent lipid peroxidation in bovine heart submitochondrial particles
25. 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyrine (MPTP) and free radicals in vitro.
26. Studies on the neurotoxicity of 1‐methyl‐4‐phenyl‐1.2.3.6‐tetrahydropyrine: Inhibition of NAD‐linked substrate oxidation by its metabolite, 1‐methyl‐4‐phenylpyridinium
27. Inhibition of NADH‐linked oxidation in brain mitochondria by 1‐methyl‐4‐phenylpyridine, a metabolite of the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetra‐hydropyridine
28. 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) and 1‐methyl‐4‐phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes
29. The mechanism of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine toxicity: Role of intracellular calcium
30. Inhibition of mitochondrial respiration by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyrine (MPTP) in mouse brain in vivo.
31. Depletion of glutathione in brainstem of mice caused by N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine is prevented by antioxidant pre‐treatment
32. Effect of 1‐methyl‐4‐phenyl‐1,2,3,6‐tertahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse
33. Transient nigral ubiquinone depletion after single MPTP administration in mice
34. MPP+‐induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis
35. Parkinson's disease: A disorder due to nigral glutathione deficiency
36. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients
37. Reduced and oxidized glutathione in human and monkey brain
38. Postmortem changes of amino compounds in human and rat brain
39. Transition metals, ferritin
40. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
41. Lipid peroxidation and Parkinson's disease
42. Brain peroxidase and catalase in Parkinson's disease
43. Glutathione peroxidase activity in Parkinson's disease brain
44. Oxygen toxicity protecting enzymes in Parkinson's disease
45. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra
46. Mitochondrial complex I deficiency in Parikinson's disease
47. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
48. Abnormalities of the electron transport chain in idiopathic Parkinson's disease
49. Mitochondrial function in Parkinson's disease
50. Deficiences in complex I subunits of the respiratory chain in Parkinson's disease
51. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence
52. Mitochondrial DNA analysis in Parkinson's disease
53. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect
54. Studies on Parkinson's disease including X‐ray fluorescent spectroscopy of formalin fixed brain tissue
55. Increased iron (III) and total iron content in post mortem substantia nigra of parkin‐sonian brain
56. Biochemical fundamentals of Parkinson's disease
57. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
58. Brain iron and ferritin in Parkinson's disease and Alzheimer's disease
59. Selective increase of iron in substantia nigra zona compacta of Parkinson's disease
60. Distribution of arsenic, manganese, and selenium in the human brain in chronic renal insufficiency, Parkinson's disease, and amyotrophic lateral sclerosis
61. Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: An X‐ray microalalysis
62. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains
63. Decreased ferritin levels in brain in Parkinson's disease
64. Ferritin in the cerebrospinal fluid of patients with Parkinson's disease
65. Study of movement disorders and brain iron by MR
66. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration
67. Alterations in the levels of iron and ferritin and other trace metals in Parkinso's disease and other neurodegenerative disease affecting the basal ganglia
68. Protection against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine neurotoxicy by the antioxidant ascorbic acid
69. Ascorbic acid reduces the dopamine depletion induced by MPTP
70. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1‐methyl‐4‐phenylpyridinium ion
71. Partial proptection from the dopaminergic neurotoxin N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine by four different antioxidants in the mouse
72. Depletion of glutathione in brainstem of mice caused by N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine is prevented by antioxidant pre‐treatment
73. MPTP toxicity in mouse brain and vitamin E
74. Induction by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice
75. Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in the mouse
76. α‐Tocopherol and Bcarotene do not protect marmosets against the dopaminergic neurotoxicity of N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
77. Treatment with GM1 ganglioside restores striatal dopamine in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated mouse
78. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
79. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP‐treated mice
80. Protection of substantia nigra from MPP+neurotoxicity by N‐methyl‐D‐aspartate antagonists
81. Protection against the dopaminergic neurotoxicity of 1‐methyl‐4‐phenyl‐1,2,5,6‐tetrahydropyridine by monoamine oxidase inhibitors
82. Pargyline prevents MPTP‐induced parkinsonism in primates
83. Pargyline and deprenyl prevent the neurotoxicity of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MMPTP) in monkeys
84. (‐)‐Deprenyl leads to prolongation of L‐DOPA efficacy in Parkinson's disease
85. Effect of deprenyl on the progression of disability in early Parkinson's disease
86. The effect of deprenyl (Selegiline) on the natural history of Parkinson's disease
87. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
88. Protection against DSP‐4‐induced neurotoxicity by deprenyl is not related to its inhibition of MAO B